EUVIMED · CrossrefJournal
Annals of Oncology
ISSN 0923-7534 · Elsevier BV
Latest articles
1RO Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
2RO Retrospective exploratory biomarker (BM) analyses from evERA breast cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) in the post-CDK4/6 inhibitor (i) setting
3RO 18F-FES PET–defined whole-body ER heterogeneity identifies endocrine responsiveness and predicts survival in ER+/HER2− metastatic breast cancer (MBC): Results of a prospective international clinical trial
4RO Target switching with conserved-payload novel ADCs in patients with metastatic breast cancer following prior ADC therapy (SWITCH): A prospective, open-label, phase 2 platform trial
5RO Safety and efficacy of SYS6043, a novel B7-H3—targeting antibody-drug conjugate, in patients with advanced breast cancer
6P Machine learning model based on pathomics features predicts T-DXd response in advanced breast cancer
7P Impact of ctDNA detected BRCA reversion mutations on outcomes of patients (pts) with BRCA-mutated metastatic breast cancer (mBC) treated with antibody-drug conjugates (ADC)
8P Clinical efficacy and predictive biomarkers of mTOR inhibition combined with endocrine therapy following progression on PI3K inhibitors in hormone receptor–positive metastatic breast cancer
9P Genomic landscape of hormone receptor positive bone-only (BO) and visceral metastases (VM) metastatic breast cancer (HR+ BC)
10P A randomized phase 3 study of disitamab vedotin (DV) versus chemotherapy (chemo) in HER2-low advanced breast cancer: overall and the liver metastasis (BCLM) subgroup results
12P DESTINY-Breast respond HER2-low Europe non-interventional study of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (mBC): Update on baseline characteristics and anti-emetic treatment
13P Sacituzumab govitecan in heavily pretreated and elderly patients with metastatic triple-negative breast cancer: A real-world multicentre study
14P Long-term real-world overall survival with first-line palbociclib + aromatase inhibitor (AI) vs AI alone in HR+/HER2− metastatic breast cancer: A 10-year retrospective US study
15P Capivasertib plus fulvestrant in PIK3CA/AKT/PTEN-altered HR+/HER2- advanced breast cancer: A multicentre real-world study
16P Clinical characteristics and outcomes of endocrine-resistant hormone receptor positive, HER2-negative (HR+/HER2−) advanced breast cancer: Insights from the AGO-B CAPTOR trial
17P Final long-term outcomes of palbociclib-fulvestrant vs. placebo-fulvestrant in HR+/HER2‒ endocrine-sensitive advanced breast cancer: GEICAM/2014-12 (FLIPPER) phase II trial
18P Prolonged progression-free survival in patients with HR+ HER2- advanced breast cancer treated with ribociclib + endocrine therapy in the RIBANNA trial
19P Ribociclib plus endocrine therapy versus chemotherapy in patients with rapidly progressive HR+/HER2− advanced breast cancer: A multicenter phase II study with external controls
20P 5-year update for the Concept Trial 3-weekly cabazitaxel (CAB) chemotherapy (CCT) vs weekly paclitaxel (Taxol) CCT in the first line treatment of HER2 negative metastatic breast cancer (MBC)
22P Quality of life in patients with bone metastases receiving reduced denosumab: A randomized phase III non-inferiority trial SAKK 96/12 REDUSE
23P Updated interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS breast cancer (BC): A phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with oestrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC)
24P A nationwide population-based cohort study on patients with locoregionally advanced (N3) or de novo metastatic breast cancer treated in Sweden 2007-2023
25P Defining and describing the population of women living with Treatable but not Curable breast cancer in England: A population-based retrospective cohort study
26P Efficacy and safety of anlotinib-based therapy in advanced breast cancer: A real-world study
27P Local treatment in metastatic breast cancer with oligoprogression: A retrospective cohort study and reconstructive individual patient data meta-analysis
28P Platinum – based doublet chemotherapy in metastatic breast cancer with liver visceral crisis: A retrospective cohort study
29P Impact of sacituzumab govitecan dose reduction on time to treatment discontinuation in second-line metastatic triple-negative breast cancer
30P Enhanced detection by multiparametric WB-MRI in metastatic breast cancer management: Prospective results
32P Longitudinal gut microbiome profiling during abemaciclib or ribociclib therapy in HR-positive/HER2-negative breast cancer
33P Quality of life in HER2-low unresectable or metastatic breast cancer treated with trastuzumab deruxtecan and sacituzumab govitecan
Volumes
2026 · 6,2182025 · 5,4172024 · 4,0812023 · 4,2972022 · 4,1692021 · 3,5592020 · 3,7712019 · 4,8272018 · 4,1002017 · 4,4342016 · 4,4432015 · 2,8282014 · 3,0172013 · 1,6382012 · 3,6772011 · 6822010 · 7522009 · 5872008 · 7882007 · 6592006 · 6912005 · 6102004 · 4962003 · 4402002 · 5282001 · 6822000 · 6611999 · 7921998 · 5881997 · 5641996 · 5671995 · 4261994 · 5201993 · 4181992 · 4631991 · 3441990 · 197
EUVIMED